0001564590-20-049655.txt : 20201102 0001564590-20-049655.hdr.sgml : 20201102 20201102161604 ACCESSION NUMBER: 0001564590-20-049655 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201102 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201102 DATE AS OF CHANGE: 20201102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DURECT CORP CENTRAL INDEX KEY: 0001082038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943297098 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31615 FILM NUMBER: 201280646 BUSINESS ADDRESS: STREET 1: 10260 BUBB RD CITY: CUPERTINO STATE: CA ZIP: 95014 BUSINESS PHONE: 4087771417 MAIL ADDRESS: STREET 1: 10260 BUBB ROAD CITY: CUPERTINO STATE: CA ZIP: 95014 8-K 1 drrx-8k_20201102.htm 8-K drrx-8k_20201102.htm
false 0001082038 0001082038 2020-11-02 2020-11-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 2, 2020

Date of Report

(Date of earliest event reported)

 

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

000-31615

 

94-3297098

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

10260 Bubb Road

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

 

 

Common Stock $0.0001 par value per share

Preferred Share Purchase Rights

DRRX

The NASDAQ Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

2

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chief Medical Officer

On November 2, 2020, DURECT Corporation (the “Company”) appointed Norman L. Sussman, MD FAASLD, age 68, as its Chief Medical Officer. Dr. Sussman has extensive clinical experience and expertise in the liver disease field and brings over 30 years of clinical research and development experience in academia and industry. He joins DURECT from Baylor College of Medicine, where he was an Associate Professor of Medicine and Surgery. Dr. Sussman has been a faculty member of Baylor College of Medicine intermittently since 1985. During this time, he has served as a Principal Investigator for research focused on the assessment and management of acute liver failure and artificial liver support. Dr. Sussman has also had leadership experience in industry as the founder and Vice President of both Amphioxus Cell Technologies from 1995 to 2003 and Hepatix, Inc from 1993 to 1995. Most recently, he has also served in senior leadership roles as a member of the Baylor Faculty Senate and as Director of the telehealth program, Project ECHO®, at Baylor St. Luke’s Medical Center.

 

Dr. Sussman received his MBBCh from the University of the Witwatersrand in Johannesburg, South Africa. He then completed his residency at St. Louis University Hospital and his post-doctoral fellowship at Washington University. He is Board Certified in Internal Medicine, Gastroenterology, and Transplant Hepatology. Dr. Sussman is also a Fellow of the American Association of the Study of Liver Disease, which is a designation that recognizes his superior level of professional achievement in the field of hepatology.

 

In connection with his appointment, the Company and Dr. Sussman entered into an offer letter (the “Offer Letter”). Pursuant to the Offer Letter, Dr. Sussman will receive a base salary of $400,000 annually. Dr. Sussman is eligible to receive an annual bonus equal to 40% of his base salary (pro-rated for 2020). In connection with the start of his employment, Dr. Sussman was provided with a relocation allowance of $250,000, less applicable income and employment taxes (partially refundable if his employment is terminated for cause (as defined in the Company’s Change of Control Policy).  He will also be granted a stock option to purchase 200,000 shares of the Company’s common stock that will vest over a four-year period with a one-year cliff. Additionally, Dr. Sussman will be granted a stock option to purchase 50,000 shares of the Company’s common stock which will vest immediately upon the first FDA approval of a DUR-928 New Drug Application. Dr. Sussman is eligible to participate in the Company’s employee benefit plans on the same basis as generally made available to other employees of the Company, and he will enter into the Company’s standard form of indemnification agreement for the Company’s officers and directors. Dr. Sussman’s stock option awards will be subject to the terms of the Company’s Change of Control Policy, which provides for certain vesting and severance benefits for officers in the event of termination in connection with a change of control.

 

The foregoing description of the Offer Letter is not complete and is qualified in its entirety by reference to the full text of the Offer Letter which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

On November 2, 2020, DURECT issued a press release attached hereto as Exhibit 99.1 and incorporated herein by reference relating to the appointment described above.

 

There are no family relationships between Dr. Sussman and any director or officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

 


3

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

 

10.1*

Offer letter between Norman L. Sussman and DURECT Corporation dated October 12, 2020

 

 

 

 

99.1

Press Release of DURECT Corporation dated November 2, 2020

 

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Management contract or compensatory plan or arrangement.

 

 


          

 

 

4

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DURECT Corporation

 

 

 

 

 

Date: November 2, 2020

 

By:

 

/s/ James E. Brown

 

 

 

 

    James E. Brown

    President and Chief Executive Officer

    

 

 

 

 

 

    

 

5

 EX-10.1 2 drrx-ex101_7.htm EX-10.1 drrx-ex101_7.htm

 

 

Exhibit 10.1

 

October 12, 2020

 

Norman L Sussman, MD FAASLD

Via electronic delivery

 

Dear Norman:

 

It is a pleasure to confirm the offer extended to you to join DURECT Corporation, located at 10260 Bubb Road, Cupertino, California, 95014, as Chief Medical Officer, reporting directly to the Chief Executive Officer.  We would like your start date to be November 2, 2020, but will depend on when you successfully complete a pre-employment drug screening and background verification.  As an exempt, regular employee, your starting semi-monthly salary will be $16,666.67, which equates to $400,000.00 on an annual basis. In addition, within 30 days following your commencement of employment, you will be granted an option to purchase 200,000 shares of DURECT Common Stock.  The vesting associated with these options are as follows: Stock options shall vest as to one-fourth (1/4) of the total shares subject to the option on the one-year anniversary of the date of grant and as to one-sixteenth (1/16) of the total shares subject to the option at the end of each three-month period following the one-year anniversary of the grant. The per share exercise price for these options will be the fair market value of DURECT Corporation’s Common Stock on the date of the grant of the options.

 

Additionally, within 30 days following your commencement of employment, you will be granted an option to purchase 50,000 shares of DURECT Common Stock to be vested immediately upon the first FDA approval of a DUR-928 New Drug Application (NDA). The per share exercise price for these options will be the fair market value of DURECT Corporation’s Common Stock on the date of the grant of the options. You will be eligible for annual equity grants commensurate with your position as Chief Medical Officer beginning calendar year 2021.

 

DURECT will provide you with a relocation allowance of $250,000.00, less applicable income and employment taxes withheld.  DURECT will reimburse you for eligible expenses you incur up to a maximum of the amount of the relocation allowance.  Eligible expenses will include (1) commute travel to and from DURECT’s offices in California, including airfare to and from California from Texas prior to your moving to California; (2) rent or hotel, rental car, etc. incurred when you travel to California to work at DURECT’s offices in California prior to your moving to California; and (3) expenses related to relocating from your home in Texas to California (or purchasing, leasing or renting a second home in California) such as travel to look at homes, moving expenses, rent, down payment on a home or condominium, mortgage payments, etc.  Any amount of such expenses you incur above the relocation allowance amount will not be reimbursed by DURECT. For clarity, business travel on behalf of the company will be reimbursed separately according to DURECT’s travel policy and will not count against the relocation allowance. As a condition of

DURECT Corporation | 10260 Bubb Road | Cupertino, CA 95014 | 408.777.1417CONFIDENTIAL

 

receiving the relocation allowance, you agree that if you voluntarily terminate your employment (other than as a result of your death, disability or constructive termination as defined in the Change of Control policy) during the first two years with DURECT Corporation, or if your employment is terminated by DURECT Corporation for cause (as defined in the Change of Control policy), you agree that you will repay a pro-rated portion of your reimbursed eligible expenses back to the company. The prorated portion to be repaid will be calculated by multiplying the amount of reimbursed eligible expenses (only those expenses listed under eligible expenses (3) above) by a fraction, the numerator of which will be equal to twenty-four minus the number of full months you were employed since your start date, and the denominator of which is twenty-four. You will be responsible for any income and employment taxes incurred as a result of DURECT reimbursing you for these eligible expenses.

 

You will be eligible for the equivalent annual bonus that all other Chief-level employees of the Company are eligible for, which is currently 40% of your annual base salary, with a breakdown of 95% based on corporate and 5% from personal objectives.  This bonus will be subject to pro-ration based on your start date.

 

In addition, your option awards will be subject to the terms of the Company’s change of control policy, which provides for certain vesting and severance benefits for Vice Presidents and above in the event of a qualifying termination of employment in connection with or within twenty-four months following a change in control.

 

Benefits

Effective the first of the month following your start date, you will be eligible to participate in the benefits enjoyed by an indefinite term employee, including medical, dental, vision, life and disability insurances.  You will be eligible for paid holidays, vacation accrual, and sick leave.  You may elect to participate in the 401(k) savings plan, the Employee Stock Purchase Plan, and a Section 125 Cafeteria Plan according to the terms and conditions governing participation in the plans.  If the terms and conditions governing any such benefit plan differ from any provision of

this letter, the plan documents containing these terms and conditions will govern and take precedence. The Company agrees to pay your reasonable legal expenses incurred in the negotiation of this agreement.

 

This offer is contingent upon successful completion of a background investigation and pre-employment drug screening test due to the fact that DURECT is engaged in the development and manufacture of pharmaceutical products, including controlled substances.  Your representing agency, Spencer Stuart, will conduct your background investigation.  As for your pre-employment drug screening test, you will be notified by Justifacts Credential Verification, Inc. and given instruction on how to complete the drug check verification.  This must be completed and returned prior to your start date.  

 

Authorization to Work

Federal regulations require that you establish your identity and authorization to work in this country, so this offer is necessarily contingent upon such proof.  Enclosed is a description of the

DURECT Corporation | 10260 Bubb Road | Cupertino, CA 95014 | 408.777.1417CONFIDENTIAL

 

original documents you will be required to bring on your first day of work, at which time we will meet with you to examine the original documents and ask that you complete the required “INS” form in our presence.

 

Agreements

The enclosed “Confidential Information and Invention Assignment Agreement” must be signed by you before you start your first day of work.  Please sign both copies of the Agreement and return one copy.  You may retain the duplicate for your records.

 

Your employment at DURECT is for an unspecified period of time and your relationship with the Company is and shall continue to be at-will, as defined under applicable law, meaning that either you or DURECT may terminate your employment relationship at any time for any reason or no reason, with or without notice.

 

Please indicate that these terms and conditions are acceptable and confirm your acceptance of this offer by signing and dating the original of this letter and returning it by October 14, 2020. You may retain a duplicate for your records.

 

Congratulations on your offer to join DURECT Corporation; we look forward to working with you.  Please do not hesitate to call me directly at (408) 777-1419 if you have any questions.

 

Sincerely,

 

/s/ James E. Brown, President & CEO

James E. Brown

President and Chief Executive Officer

 

 

JEB/bs

Enclosures

 

Understood and accepted:

 

 

Signature   /s/ Norman L. Sussman, MD, FAASLDDate12-Oct-2020

       Norman Sussman, MD FAASLD

DURECT Corporation | 10260 Bubb Road | Cupertino, CA 95014 | 408.777.1417CONFIDENTIAL

 

 EX-99.1 3 drrx-ex991_6.htm EX-99.1 drrx-ex991_6.htm

Exhibit 99.1

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer

 

CUPERTINO, Calif., November 2, 2020/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer, effective immediately. In this new role, Dr. Sussman will oversee the clinical development of DURECT’s pipeline including multiple indications for its lead investigational drug candidate DUR-928.

 

“We are excited to welcome Dr. Sussman as our Chief Medical Officer as we continue to advance DUR-928 through clinical development for the treatment of alcoholic hepatitis (AH), nonalcoholic steatohepatitis (NASH), and other indications,” stated James E. Brown, D.V.M., President and Chief Executive Officer of DURECT. “Dr. Sussman is a renowned hepatologist with a proven track record in clinical research of liver diseases. We believe he will provide critical support in advancing our clinical programs and we look forward to his contributions.”

 

Dr. Sussman commented, “I am delighted to be joining DURECT at this exciting time for the company as it prepares to initiate dosing in a potentially pivotal Phase 2b trial in AH and continues to advance clinical programs for other indications involving acute organ injury and chronic liver diseases. DUR-928 is an epigenetic regulator with a unique mechanism of action that has potential to transform the treatment of these diseases. I look forward to leveraging my clinical experience as I join a talented and dedicated team at DURECT working to bring desperately needed, potentially life-saving therapies to patients with no good therapeutic options.”

 

Dr. Sussman has extensive clinical experience and expertise in the liver disease field and brings over 30 years of clinical research and development experience in academia and industry. He joins DURECT from Baylor College of Medicine, where he was an Associate Professor of Medicine and Surgery. Dr. Sussman has been a faculty member of Baylor College of Medicine intermittently since 1985. During this time, he has served as a Principal Investigator for research focused on the assessment and management of acute liver failure and artificial liver support. Dr. Sussman has also had leadership experience in industry as the founder and Vice President of both Amphioxus Cell Technologies from 1995 to 2003 and Hepatix, Inc from 1993 to 1995. Most recently, he has also served in senior leadership roles as a member of the Baylor Faculty Senate and as Director of the telehealth program, Project ECHO®, at Baylor St. Luke’s Medical Center.

 

Dr. Sussman received his MBBCh from the University of the Witwatersrand in Johannesburg, South Africa. He then completed his residency at St. Louis University Hospital and his post-doctoral fellowship at Washington University. He is Board Certified in Internal Medicine, Gastroenterology, and Transplant Hepatology. Dr. Sussman is also a Fellow of the American Association of the Study of Liver Disease, which is a designation that recognizes his superior level of professional achievement in the field of hepatology.

 

About DURECT Corporation

 

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT’s lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique

1

 

mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival.  This drug candidate is in Phase 2 development for the treatment of alcoholic hepatitis (AH) and the treatment of COVID-19 patients with acute liver or kidney injury as well as Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT’s proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.

 

DURECT Forward-Looking Statement

 

The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat COVID-19 patients with liver or kidney injury, the potential use of DUR-928 to treat acute organ injuries, such as AH, and chronic liver diseases, such as NASH, the life saving potential of DUR-928, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, protocol changes or lack of available patients, the risk that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life saving potential of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR or approve POSIMIR with a limited label, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company’s other product candidates, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on August 4, 2020 under the heading “Risk Factors.”

 

NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation.  Other referenced trademarks belong to their respective owners.  DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

 

 

Corporate ContactMedia Contact

Mike Arenberg Alison Chen
DURECTLifeSci Communications

Chief Financial Officer+1-646-876-4932
+1-408-346-1052achen@lifescicomms.com

mike.arenberg@durect.com

2

 

 EX-101.SCH 4 drrx-20201102.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 drrx-20201102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 6 drrx-20201102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 drrx-8k_20201102_htm.xml IDEA: XBRL DOCUMENT 0001082038 2020-11-02 2020-11-02 false 0001082038 8-K 2020-11-02 DURECT CORP DE 000-31615 94-3297098 10260 Bubb Road Cupertino CA 95014 408 777-1417 false false false false Common Stock $0.0001 par value per share DRRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Nov. 02, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2020
Title of 12(b) Security Common Stock $0.0001 par value per share
Security Exchange Name NASDAQ
Trading Symbol DRRX
Entity Registrant Name DURECT CORP
Entity Central Index Key 0001082038
Entity Emerging Growth Company false
Entity File Number 000-31615
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3297098
Entity Address, Address Line One 10260 Bubb Road
Entity Address, City or Town Cupertino
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95014
City Area Code 408
Local Phone Number 777-1417
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports drrx-8k_20201102.htm drrx-20201102.xsd drrx-20201102_lab.xml drrx-20201102_pre.xml drrx-ex101_7.htm drrx-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "drrx-8k_20201102.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "drrx-8k_20201102.htm" ] }, "labelLink": { "local": [ "drrx-20201102_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "drrx-20201102_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "drrx-20201102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "drrx", "nsuri": "http://www.durect.com/20201102", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "drrx-8k_20201102.htm", "contextRef": "C_0001082038_20201102_20201102", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "drrx-8k_20201102.htm", "contextRef": "C_0001082038_20201102_20201102", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.durect.com/20201102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-20-049655-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-049655-xbrl.zip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